Adcentrx Therapeutics is using protein conjugate technology to create therapies for cancer and other diseases. Antibody-drug conjugates (ADCs) are a therapeutic approach that deliver toxic payloads into a diseased cell. However, ADCs come with limitations such as fast clearance leading to lower efficacy and premature release of payloads causing off-target toxicity. Adcentrx is using their “Toolbox” to pioneer stable conjugation chemistry they refer to as the i-ConjugationTM technology. Using this technology, Adcentrx is improving payload delivery to the target, allowing higher dosing and better tumor penetration. In addition, Adecntrx is optimizing the targeting moiety, linker and payload to reduce manufacturing complexity and to tackle heterogeneous tumors. 

<p>Adcentrx Therapeutics is using protein conjugate technology to create therapies for cancer and other diseases. Antibody-drug conjugates (ADCs) are a therapeutic approach that deliver toxic payloads into a diseased cell. However, ADCs come with limitations such as fast clearance leading to lower efficacy and premature release of payloads causing off-target toxicity. Adcentrx is using their “Toolbox” to pioneer stable conjugation chemistry they refer to as the i-ConjugationTM technology. Using this technology, Adcentrx is improving payload delivery to the target, allowing higher dosing and better tumor penetration. In addition, Adecntrx is optimizing the targeting moiety, linker and payload to reduce manufacturing complexity and to tackle heterogeneous tumors. </p>


Adcentrx Therapeutics

Founded: 2021
Location: San Diego, CA
Employee range: 1-50
Clinical stage: Clin1
Therapy area: Solid tumors
Drug types: ONC
Lead product: ADRX-0706
Funding: 10-100M

Drug notes:

About:

Jobs: